Hello,
We are preparing for a Joint Commission visit and working on USP <797> compliance in ORs/procedural areas. We are hoping you would be willing to share information about your sterile product practices in these areas and any recent experience with TJC surveyors on this topic.
- Do you consider preparing sterile products in ORs/procedural areas (Examples: drawing up a dose from a vial, drawing propofol into a syringe, etc.) to be immediate-use compounding or per approved labeling?

Good morning,

What strategies are you all employing to capture data around PI.01.01.01 EP5 (Adverse events related to using moderate or deep sedation or anesthesia)?

We recently had a near miss reported due in part to the new TJC naming requirement for newborns. Baby [Mouse, Girl Minnie] had an order intended for Mom [Mouse, Minnie].

1. Have you had reports related to this new naming convention?
2. How has your institution implemented this requirement? (e.g. Mouse, Minnie Girl; Mouse, Minnie Babygirl; Mouse, Girl Minnie; Mouse, Minnie's Girl)
3. Are you limited in characters or format by your EHR?

Thanks!
Liz